Higher pre-operative HDL-C levels were not associated with a reduced risk of MACE (HR 1.43, P=0.11) or death in patients with coronary artery disease undergoing elective CABG.
Cohort (n=1,548)
No
Are high pre-operative HDL-C levels associated with reduced cardiovascular events in patients with coronary artery disease undergoing elective CABG?
Higher pre-operative HDL-C levels do not protect against, and may even be associated with increased, major adverse cardiovascular events in CAD patients undergoing CABG.
Estimación del efecto: HR 1.43
Tasa de eventos absoluta: 32.9% vs 23.9%
valor p: p=0.11
AIMS: Primary prevention studies have confirmed that high-density lipoprotein cholesterol (HDL-C) levels are strongly associated with reduced cardiovascular events. However, recent evidence suggests that HDL-C functionality may be impaired under certain conditions. In the present study, we hypothesize that HDL-C may lose their protective role in the secondary prevention of coronary artery disease (CAD). METHODS AND RESULTS: A consecutive series of 1548 patients undergoing isolated first-time elective CABG at one institution between 2004 and 2009 was studied. According to the ATPIII criteria, pre-operative HDL-C values were used to identify patients with high (Group A) vs. low HDL-C (Group B). To eliminate biased estimates, a propensity score model was built and two cohorts of 1:1 optimally matched patients were obtained. Cumulative survival and major adverse cardiovascular events (MACE) were analysed by means of Kaplan-Meier method. Cox proportional-hazards regression models were used to identify independent predictors of MACE and death. Propensity matching identified two cohorts of 502 patients each. At a median follow-up time of 32 months, there were 44 out of 502 (8.8%) deaths in Group A and 36 out of 502 deaths in Group B (7.2%, HR 1.19; P = 0.42). MACE occurred in 165 out of 502 (32.9%) in Group A and 120 out of 502 (23.9%) in Group B (P = 0.04). Regression analysis showed that pre-operative HDL-C levels were not associated with reduced but rather increased MACE occurrence during follow-up (HR 1.43, P = 0.11). CONCLUSION: Higher HDL-C levels are not associated with reduced risk of vascular events in CAD patients undergoing CABG. Our findings may support efforts to improve HDL-C functionality instead of increasing their levels.
Angeloni et al. (Wed,) conducted a cohort in Coronary artery disease (n=1,548). High HDL-C vs. Low HDL-C was evaluated on Major adverse cardiovascular events (MACE) (HR 1.43, p=0.11). Higher pre-operative HDL-C levels were not associated with a reduced risk of MACE (HR 1.43, P=0.11) or death in patients with coronary artery disease undergoing elective CABG.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: